XML 140 R32.htm IDEA: XBRL DOCUMENT

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In January 2020, the Company completed the Transactions discussed in Note 3. Concurrent with entering into the TS Biotechnology Sale on January 1, 2020, the Company also entered into a subscription agreement with TS Biotechnology pursuant to which TS Biotechnology purchased 5,972,696 shares of the Company's common stock for $35,000 on January 31, 2020. In February 2020, the Company and Fibrocell mutually agreed to terminate Fibrocell ECC 2. The Company is considering the impact of this termination on its 2020 financial results.